Skip to main content

Table 1 Basic characteristics

From: High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study

Characteristic

Cases (DM)

Controls

P value

n

82

86

 

Gender (male) – n (%)

61 (74)

61 (74)

0.615

Age (y) – mean (SD)

62 (±8)

62 (±7)

0.941

BMI (kg/m2) – mean (SD)

28 (±4)

27 (±4)

0.12

Active smoking – n (%)

4 (5)

6 (7)

0.747

FRS – mean (SD)

26 (±13)

16 (±9)

<0.001

Comorbidities – n (%)

 Hypertension

45 (55)

47 (55)

0.976

 Hyperlipidemia

61 (74)

62 (72)

0.737

Hypoglycemic medications – n (%)

 Biguanides

58 (70)

N/A

 

 GLP1-RA

3 (4)

N/A

 

 DPP-4 antagonists

25 (30)

N/A

 

 SU/Meglitinides

10 (12)

N/A

 

 Insulin

8 (10)

N/A

 

Medications – n (%)

 Beta blockers

16 (20)

12 (14)

0.334

 Calcium channel blockers

14 (17)

17 (20)

0.653

 ACEi/ARB

33 (40)

31 (36)

0.575

 Diuretics

4 (5)

9 (10)

0.175

 Statins

53 (65)

46 (54)

0.142

Laboratory values – mean (SD)

 Hemoglobin (g/dl)

14 (±1)

14 (±1)

0.635

 Platelets (K/microL)

222 (±54)

216 (±52)

0.401

 Fasting plasma glucose (mg/dl)

136 (±29)

91 (±8)

<0.001

 HbA1c (%) (mmol/mol)

6.7 (±0.9) (49.7)

5.4 (±0.3) (35.5)

<0.001

 LDL (mg/dl)

109 (±24)

121 (±24)

<0.001

 HDL (mg/dl)

46 (±14)

50 (±12)

0.040

 Total Cholesterol (mg/dl)

162 (±30)

179 (±31)

<0.001

 eGFR (mL/min/1.73 m2)

79 (±19)

76 (±15)

0.289

  1. DM type 2 diabetes mellitus, BMI Body Mass Index, FRS Framingham Risk Score, GLP-1RA Glucagon Like Peptide-1 Receptor Agonist, DPP-4 Dipeptidyl Peptidase-4, SU Sulfanilurea; ACEi Angiotensin Converting Enzyme Inhibitor, ARB Angiotensin Receptor Blockers, HbA1C Hemoglobin A1C, LDL Low Density Lipoprotein, HDL High Density Lipoprotein, eGFR Estimated Glomerular Filtration Rate